BiotechTube

AMG531

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Aplastic Anemia

Conditions

Aplastic Anemia

Trial Timeline

Apr 14, 2014 → Nov 7, 2017

NCT ID
NCT02094417

About AMG531

AMG531 is a phase 2 stage product being developed by Kyowa Kirin for Aplastic Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02094417. Target conditions include Aplastic Anemia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02094417Phase 2Completed

Competing Products

20 competing products in Aplastic Anemia

See all competitors
ProductCompanyStageHype Score
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
41
efatutazone + paclitaxelDaiichi SankyoPhase 2
52
AlefaceptAstellas PharmaPhase 1
33
RomiplostimKyowa KirinPhase 2/3
65
Lenvatinib 24 mgEisaiPhase 2
52
RomiplostimKyowa KirinPhase 2/3
65
RomiplostimKyowa KirinPhase 2/3
65
Lenvatinib + NivolumabOno PharmaceuticalPhase 2
52
Hetrombopag Olamine TabletJiangsu Hengrui MedicinePhase 1
33
Hetrombopag Olamine + PlaceboJiangsu Hengrui MedicinePhase 3
77
Trappa ethanolamine tablets ; ciclosporin + Placebo ; ciclosporinJiangsu Hengrui MedicinePhase 2
52
Hetrombopag Olamine Tablet；Ciclosporin Soft CapsuleJiangsu Hengrui MedicinePhase 1
33
Hetrombopag Olamine TabletJiangsu Hengrui MedicinePhase 1
33
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1/2
41
Hetrombopag Olamine+Standard Therapy + Placebo+Standard TherapyJiangsu Hengrui MedicinePhase 3
77
durvalumab + tremelimumabAstraZenecaPhase 1
33
PembrolizumabMerckPhase 2
52
PosaconazoleMerckPhase 2
52
Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 + Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 + Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 + Extension CohortNovartisPhase 1/2
41
LDK378 + AUY922NovartisPhase 1
33

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85